Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Why Did Eli Lilly Stock Jump 15% in April?
10:56am, Monday, 08'th May 2023
Eli Lilly published positive clinical trial results on a weight-loss drug and an early-stage Alzheimer's treatment candidate. Though its Q1 results fell short of analysts' estimates, investors were pl
Where Will Eli Lilly Be in 3 Years?
05:57am, Monday, 08'th May 2023
Eli Lilly's near-term outlook is quite favorable. The only major constraint it faces is competition in several drug markets.
3 Things About Eli Lilly That Smart Investors Know
05:05am, Monday, 08'th May 2023
The next couple of years will see Eli Lilly's top and bottom lines swell. Its debt load looks like more of a problem than it actually is.
2 Top Healthcare Stocks Defying the Bear Market
08:14am, Sunday, 07'th May 2023
Eli Lilly's tirzepatide could be a weight-loss blockbuster. Merck continues to add indications for oncology therapy Keytruda.
2 Best Biotech Stocks to Buy Right Now
07:55am, Saturday, 06'th May 2023
Eli Lilly and Amgen both boast exceptional product portfolios and pipelines. The two companies pay growing dividends to shareholders.
Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?
10:15am, Friday, 05'th May 2023
There are often trade-offs to make when selecting passive income stocks. Eli Lilly's next couple of years will see its revenue burgeon by billions.
This Top Fund Manager Buys Growth Stocks Without Paying Too Much
07:00am, Friday, 05'th May 2023
Daniel Morris, manager of top mutual fund Manor Growth Fund (MNRGX), admits he has a conservative streak. The post This Top Fund Manager Buys Growth Stocks Without Paying Too Much appeared first on In
Which Healthcare Stock Is a Compelling Pick for the Long Haul?
03:29pm, Thursday, 04'th May 2023
Investors remain puzzled due to persistent macro challenges, continued interest rate hikes, and the regional banking crisis. Given the ongoing uncertainties, sectors that are resilient during economic
Eli Lilly's Alzheimer's Breakthrough: A Game Changer For Investors And Patients
10:55am, Thursday, 04'th May 2023
Eli Lilly's donanemab shows promise in slowing Alzheimer's progression, offering significant market potential. Competitive landscape between Eli Lilly, Eisai, and Biogen could drive further innovation
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
10:41am, Thursday, 04'th May 2023
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should Investors Buy This Hot Growth Stock?
10:15am, Thursday, 04'th May 2023
Eli Lilly's financial results were challenged by a recent decision from the FDA. The stock's dividend payout is modest but positioned to grow robustly.
Here's the Best Reason to Buy Eli Lilly Stock Right Now
09:23am, Thursday, 04'th May 2023
The pharmaceutical giant's first-quarter results were hardly impressive. But the company's drug Mounjaro recently reported an important clinical win.
These Have Been 3 of the Best-Performing Healthcare Stocks Since 2020
05:57am, Thursday, 04'th May 2023
Demand for Moderna's COVID-19 vaccine will taper off this year, but investors remain bullish on its prospects. McKesson is a top distributor of pharmaceuticals and a key cog in the healthcare industry
Should You Buy Eli Lilly Stock Now?
05:13am, Thursday, 04'th May 2023
Eli Lilly announced the successful results of a phase 3 trial with donanemab, an experimental treatment for Alzheimer's disease. Treatment with the Alzheimer's disease candidate appeared to reduce the
Obesity drug could be a 'big upside' for Eli Lilly, says Wells Fargo's Mohit Bansal
07:19pm, Wednesday, 03'rd May 2023
Mohit Bansal, Wells Fargo managing director, joins 'Fast Money' to talk Eli Lilly drug trials, it's competition with Biogen for an alzheimer's drug, and more.
